CVC Capital Partners And 2 Other European Stocks That May Be Trading Below Their Estimated Value

Simply Wall St

As European markets navigate concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut, the pan-European STOXX Europe 600 Index recently ended 2.21% lower, reflecting broader market apprehensions. In such an environment, identifying stocks that may be trading below their estimated value can be particularly appealing to investors seeking opportunities amidst prevailing market volatility.

Top 10 Undervalued Stocks Based On Cash Flows In Europe

NameCurrent PriceFair Value (Est)Discount (Est)
YIT Oyj (HLSE:YIT)€3.02€5.9649.4%
STEICO (XTRA:ST5)€20.25€40.1749.6%
Spindox (BIT:SPN)€12.90€25.1748.7%
Roche Bobois (ENXTPA:RBO)€35.00€69.4749.6%
KB Components (OM:KBC)SEK41.75SEK83.2649.9%
HMS Bergbau (XTRA:HMU)€52.00€103.8849.9%
Exel Composites Oyj (HLSE:EXL1V)€0.395€0.7849.7%
Esautomotion (BIT:ESAU)€3.12€6.1949.6%
EcoUp Oyj (HLSE:ECOUP)€1.36€2.6648.9%
Delivery Hero (XTRA:DHER)€16.31€31.9749%

Click here to see the full list of 198 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Here we highlight a subset of our preferred stocks from the screener.

CVC Capital Partners (ENXTAM:CVC)

Overview: CVC Capital Partners plc is a private equity and venture capital firm that focuses on middle market secondaries, infrastructure and credit, management buyouts, leveraged buyouts, growth equity, mature investments, recapitalizations, strip sales, and spinouts with a market cap of €15 billion.

Operations: The firm's revenue is primarily derived from its Private Equity segment (€951.11 million), followed by Credit (€197.65 million) and Secondaries (€124.38 million).

Estimated Discount To Fair Value: 22.2%

CVC Capital Partners is trading at €14.12, significantly below its estimated fair value of €18.14, suggesting undervaluation based on discounted cash flow analysis. Despite high debt levels, the company's earnings are forecast to grow 13.07% annually, outpacing the Dutch market's 11.7%. Recent earnings showed substantial growth with net income reaching €573.73 million for H1 2025 compared to €44.79 million a year ago, highlighting strong cash flow potential amidst ongoing strategic M&A activities in enterprise tech sectors.

ENXTAM:CVC Discounted Cash Flow as at Nov 2025

Sandoz Group (SWX:SDZ)

Overview: Sandoz Group AG is a global company that develops, manufactures, and markets generic pharmaceuticals and biosimilars, with a market cap of CHF23.95 billion.

Operations: The company's revenue is primarily derived from its Pharmaceuticals segment, which generated $10.59 billion.

Estimated Discount To Fair Value: 37.4%

Sandoz Group is trading at CHF55.6, substantially below its fair value estimate of CHF88.81, indicating undervaluation based on cash flow analysis. The company's earnings are projected to grow significantly at 29.8% annually, surpassing the Swiss market's 10.4% growth rate. Despite low return on equity forecasts and interest payments not well covered by earnings, recent strategic moves like the global license agreement for a biosimilar oncology medicine highlight potential for enhanced cash flows and market positioning in the biosimilars sector.

SWX:SDZ Discounted Cash Flow as at Nov 2025

Straumann Holding (SWX:STMN)

Overview: Straumann Holding AG is a global provider of tooth replacement and orthodontic solutions, with a market cap of CHF15.74 billion.

Operations: The company's revenue is derived from its operations, with CHF1.38 billion from Europe, Middle East and Africa (EMEA), CHF783.18 million from North America (NAM), CHF655.77 million from Asia Pacific (APAC), and CHF292.92 million from Latin America (LATAM).

Estimated Discount To Fair Value: 38.4%

Straumann Holding is trading at CHF98.7, significantly below its estimated fair value of CHF160.28, suggesting it is undervalued based on cash flow analysis. Earnings are projected to grow 15% annually, outpacing the Swiss market's 10.4%. Recent strategic partnerships with Smartee aim to enhance profitability and innovation in orthodontics, potentially boosting cash flows further. Despite modest revenue growth forecasts of 8.8%, Straumann's strong international presence supports its long-term growth prospects.

SWX:STMN Discounted Cash Flow as at Nov 2025

Summing It All Up

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if CVC Capital Partners might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com